Articles tagged with Alzheimer Disease
A TGen-led team found a link between the brain protein KIBRA and reduced Alzheimer's disease risk in individuals with the T-allele gene. The study suggests that KIBRA may play a role in Alzheimer's disease, providing promising new targets for treatments.
A simple blood test to detect Alzheimer's disease is within sight, with a specific peptide in the blood plasma indicating increased risk. The decline of this peptide may reflect the compartmentalization of amyloid Beta 42 in the brain, occurring in people with Alzheimer's.
Researchers have discovered unique hybrid protein complexes that form when Abeta amyloid and a-synuclein interact, altering neuronal activity. This study provides a model for developing new drugs to treat these devastating neurological diseases.
Research highlights the potential benefits of antihypertensive treatment on cognitive functions in Alzheimer's disease. Studies show that treating high blood pressure may reduce the incidence of dementia and slow cognitive decline in older adults. However, more studies are needed to confirm these findings.
A home-based physical activity program improved cognitive function in adults with memory problems, compared to those who did not participate. The study found that exercise delayed recall and reduced Clinical Dementia Rating scores in participants.
A study found that recovery from brain injury increases amyloid beta levels in patients, with better neurological status correlating to higher levels. The findings suggest a new understanding of the connection between brain injury and Alzheimer's disease.
A study by Deborah A. Small and Uri Simonsohn found that people become more sympathetic towards victims suffering from the same misfortune as a close relationship, leading to increased donations to charities supporting those causes. The researchers recreated this phenomenon in an experiment where participants formed new friendships and...
Researchers describe a new computer-based technique to identify tau protein structures associated with Alzheimer's disease, offering hope for new treatments. By analyzing experimental data, they found one structure likely to play a role in the pathologic process.
Researchers at LSUHSC have identified a naturally occurring fatty acid, 2-AG, that functions as an endogenous COX-2 inhibitor, protecting brain cells from neurodegenerative diseases. The study provides new therapeutic approaches to prevent devastating disorders like stroke and Alzheimer's.
Researchers discovered compounds that interact with tau protein in three specific ways, which could lead to early diagnosis and treatment of Alzheimer's disease. These compounds may bind to tau filaments, inhibit filament formation, or drive tau protein to form filaments.
A virus that infects potatoes has been used to develop antibodies that can bind to the amyloid beta protein, a key contributor to Alzheimer's disease. Studies in mice have shown promising results, with the development of strong antibodies that can slow disease progression and improve cognitive function.
A study published in Neurology found that physical frailty is associated with Alzheimer's disease pathology in both people with and without dementia. The researchers found that participants with high levels of AD pathology had approximately twice the level of frailty compared to those with low levels.
Researchers found that individuals with lower educational achievement and smaller head sizes were more likely to develop Alzheimer's disease, suggesting an early sign of the illness. The study suggests that brain damage related to Alzheimer's may begin earlier in life, compromising intellectual ability and leading to reduced education.
A type of PET scanning may be useful in non-invasive assessment of brain plaque formation. Six patients with beta-amyloid plaques displayed a higher uptake of the marker [11C]PiB in certain brain areas compared to those without such accumulations.
A Swedish study found that living with a spouse or partner in midlife reduces the risk of developing dementia, including Alzheimer's disease. The study showed that people living alone ran twice the risk and widows/widowers faced the greatest risk of developing dementia.
The study found that patients treated with IGIV demonstrated significantly better cognitive function, daily functioning, and activities of daily living compared to those receiving placebo. The benefits persisted over 9 months, showing promise for IGIV as an antiamyloid immunotherapy for Alzheimer's disease.
Researchers found that elevated calcium levels near amyloid plaques can disrupt neuronal function, leading to cellular degeneration. This study provides a new understanding of the connection between amyloid plaques and neurodegeneration in Alzheimer's disease.
Bernardino Ghetti, a renowned Indiana University Alzheimer's disease researcher, has been awarded the Henry M. Wisniewski Award for his lifetime contributions to Alzheimer's research and understanding of dementia mechanisms.
Researchers found that individuals with a maternal history of Alzheimer's disease exhibit progressive metabolic reductions in glucose usage, particularly in areas of the brain affected by AD. This study bolsters previous findings and suggests that maternal risk for AD may be mediated through reduced brain metabolism.
NYU researchers have identified new predictors for Alzheimer's disease, including brain atrophy and biomarkers in cerebrospinal fluid. These findings may help predict individuals at high risk of developing the disease, enabling early detection and prevention.
A study found that healthy children of Alzheimer's patients who carry the APOE-4 gene demonstrate reduced functional brain connectivity between key structures. This reduction is detectable long before clinical symptoms appear, with non-carriers showing significantly better connectivity.
A new study published in The Lancet Neurology found that a small dose of the drug PBT2 improved cognitive function in early-stage Alzheimer's patients, reducing amyloid-beta levels by approximately 13% compared to placebo. The study suggests that PBT2 may have a significant effect on the underlying pathology of Alzheimer's disease.
A new study led by the University of Michigan found that people at high risk for dementia who took cholesterol-lowering statins were half as likely to develop dementia. The five-year study involved older Mexican-Americans with metabolic conditions and showed a significant reduction in dementia risk.
Women with low or high thyrotropin hormone levels have a higher risk of developing Alzheimer's disease, according to a recent study. The research found that these hormone levels were associated with an increased risk of incident Alzheimer's disease in women, but not in men.
Research suggests dementia prevalence in developing world is closer to developed countries' rates, with potential for improved health and social care systems.
Researchers found that angiotensin receptor blockers significantly decrease the occurrence and progression of dementia in patients with Alzheimer's disease or those at risk. Patients taking ARBs also showed a lower chance of developing delirium, nursing home admissions, or death.
Researchers at NYU Langone Medical Center presented several key findings on Alzheimer's disease risk factors, including a study that identified signs of brain pathology in healthy individuals. They also reported promising results from couples counseling and antibody tests against common mouth bacteria linked to Alzheimer's disease. The...
The special issue highlights promising therapeutic targets and techniques to measure the effects of disease-modifying therapies on cerebral amyloid β levels. Clinical trials are underway, and several promising drugs are headed towards clinical trials, offering cautious optimism for new AD therapeutics.
Researchers created a laboratory model to study Alzheimer's disease mechanisms at the molecular level. The model found that amyloid beta peptides cause a 'leaky' membrane, disrupting normal impulse transmission and leading to cell toxicity.
The Alzheimer's Disease Research Center at Washington University School of Medicine will lead a six-year, $16 million international collaboration to study inherited forms of Alzheimer's disease. Researchers hope to identify biomarkers in individuals with known mutations to shorten diagnosis time and develop new treatments.
Researchers report rapid improvement in verbal fluency and aphasia following perispinal etanercept administration in a novel immune-based treatment for Alzheimer's disease. The study suggests that elevated TNF-alpha levels may interfere with neural communication, which can be reversed using this approach.
A study found that immunization with Aβ42 reduced brain amyloid-β plaque formation and improved cognitive function in mice, but failed to prevent dementia progression in humans. Despite clearing associated brain plaques, immunized patients did not show improved survival or increased time to severe dementia.
Dimebon significantly improves clinical course of mild-to-moderate Alzheimer's disease, with increasing benefits over time. The drug demonstrated significant improvement in cognition, function, and behavior compared to placebo.
A Russian study found that the drug Dimebon continued to improve patients with mild to moderate Alzheimer's disease over a year, showing improvement in all five outcomes. Researchers believe it works by stabilizing mitochondria and inhibiting brain cell death.
Researchers reduce Aβ42 deposits by overexpressing NEP enzyme in fruit flies, suppressing outright neuron death and plaque accumulation. However, chronic overexpression leads to age-related axon degeneration and shortened lifespan.
A recent study found that people with higher physical fitness levels had larger brains compared to those with lower fitness, suggesting exercise may preserve brain function and reduce cognitive decline in early Alzheimer's disease. The study also revealed no relationship between fitness and brain changes in healthy individuals.
Researchers found that a higher MMSE score threshold of 27 can more effectively detect dementia in highly educated older adults. This new criterion may facilitate early detection and timely treatment of the disease.
Researchers at University of Western Ontario found a link between brain ventricle size and cognitive impairment in Alzheimer's patients. They suggest that MRI scans can measure ventricle changes to provide earlier diagnosis and assess treatment effectiveness.
Researchers have developed a plant-derived vaccine against Alzheimer's disease using transgenic tomatoes expressing human beta-amyloid protein. The study showed a strong immune response in mice, but the potency of the vaccine needs to be increased.
A study from MIT researchers found that a dietary cocktail combining omega-3 fatty acid, uridine, and choline improves memory and learning in gerbils. The combination is being tested in Alzheimer's patients, suggesting a possible beverage-based treatment for the disease.
Researchers discovered that calpain inhibitors restore normal signaling between nerve cells, improving memory in APP/PS1 mice. Calpain inhibition may slow down or stop Alzheimer's disease progression by addressing impaired cognition.
Research suggests that enhancing neprilysin production can reduce plaque formation and neuron death associated with Alzheimer's disease, but at the cost of shortening lifespan. Over-activation of neprilysin also reduces CREB protein activity and increases age-dependent axon pathology.
Researchers analyzed brain activity using fMRI to identify differences in connectivity between Alzheimer's patients and healthy individuals. They found that patients had fewer functional hubs, compromising regional connections and contributing to memory loss.
A study reveals a direct link between Alzheimer's disease-causing mutations and aberrant calcium signaling. The researchers found that this disrupted calcium release led to amyloid beta protein generation, a hallmark of the disease.
Researchers have discovered a new genetic risk factor, CALHM1, associated with late-onset Alzheimer's disease. The gene affects calcium levels and is linked to increased amyloid-ß peptides, forming brain plaques in the disease.
Researchers at Rutgers University discovered a protein that suppresses cell division in brain cells, effectively 'putting the brakes' on Alzheimer's disease. The study suggests that when this brake fails, dementia results.
A new automated system for measuring brain tissue with magnetic resonance imaging (MRI) can help physicians accurately diagnose Alzheimer's disease at an earlier stage. The technique, which uses computer software developed by researchers, shows significant promise in reducing processing time from hours to minutes.
The study demonstrates that CNI-1493 protects nerve cells against amyloid beta-induced damage in culture and improves memory and cognitive function in mice prone to developing an Alzheimer's-like disease. The drug may provide a faster and more effective treatment for Alzheimer's, offering a promising alternative to current therapies.
A study led by Florida State University has found that the APOE epsilon 4 allele is a risk factor for African-Americans as well as whites. The gene increases the risk of cognitive decline and dementia in both populations. Researchers hope to develop medicines that slow or prevent Alzheimer's disease using this newfound understanding.
Researchers found a faster disease course and increased HIV entry in patients with the apoE4 allele. The study suggests apoE4 may have clinical applicability in treating both Alzheimer's and HIV diseases.
Researchers used molecular imaging to monitor Alzheimer's disease progression, identifying those at risk and assessing therapy effectiveness. The study found that beta-amyloid imaging can detect AD earlier and distinguish it from other dementias.
Researchers have discovered that apolipoprotein E enhances the degradation of amyloid beta protein in the brain, which may lead to a powerful new treatment for Alzheimer's disease. The study found that activating liver X receptors increases lipidated ApoE levels, resulting in reduced A? plaque levels and improved memory.
Gamma-secretase modulators, a class of agents in testing to treat Alzheimer's, work by reducing long Abeta peptides and increasing shorter ones that inhibit aggregation. This could lead to new treatments for the disease, with one such drug, tarenflurbil, showing promise in patients with mild Alzheimer's.
A unique case study found a 115-year-old woman had an essentially normal brain with little evidence of Alzheimer's disease. The findings question the inevitability of cognitive decline in elderly individuals and suggest potential for preserving brain function.
Researchers found that interrupting a signaling pathway in immune system cells opened the possibility of a new strategy against Alzheimer's disease. Immune cells from outside the brain devoured plaque deposits, reducing their numbers by up to 90 percent.
Researchers at Yale University have successfully cleared up Alzheimer's plaques in mice by blocking a common immune system response, enabling treated mice to recover lost memory. The breakthrough could one day lead to the development of new dementia medications that can safely cross the blood-brain barrier.
Researchers found NSAID use reduced Alzheimer's disease risk by 23% compared to non-users. The type of NSAID did not affect the risk reduction, challenging current theories about ibuprofen's benefits.
Researchers discovered that HIV protease inhibitors can prevent photoreceptor apoptosis in mouse models of retinal detachment, reducing the cause of vision loss. CD133 expression was found not to be restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells can initiate tumors.
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer’s disease-like pathology in mice. The vaccinated mice demonstrated normal learning skills and functioning memory despite being genetically designed to develop an aggressive form of the disease.
Scientists have discovered conclusive evidence of Alzheimer's-like neurofibrillary brain tangles in an aged nonhuman primate, a breakthrough that could help understand why humans develop neurodegenerative diseases. The finding also paves the way for new treatments and therapies targeting beta-amyloid protein.